BioCentury | Sep 9, 2020
Product Development

International group of researchers call Russian COVID-19 vaccine data into question

...concerns raised in May by Phase I data from CanSino Biologics...
BioCentury | Sep 5, 2020
Product Development

Russian COVID-19 vaccine induces T cell responses, antibodies on par with convalescent plasma

...vaccine in the clinic: Johnson & Johnson (NYSE:JNJ), CanSino Biologics...
BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

...BioCentury it will no longer be running a Phase I trial of a COVID-19 vaccine from CanSino Biologics...
...retinoid derivative.TARGETSIFNƛ – Interferon ƛ BC Staff Veklury, remdesivir (GS-5734) Eiger BioPharmaceuticals Inc. Gilead Sciences Inc. BioNTech SE Pfizer Inc. Moderna Inc. Abbott Laboratories CanSino Biologics...
BioCentury | Aug 27, 2020
Product Development

Moderna's COVID-19 vaccine may work better in the elderly than competitors’

...18-55 year-olds. Each cohort included 12 individuals. Ad5-nCoV from CanSino Biologics...
BioCentury | Aug 15, 2020
Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

...some posting substantial stock gains in their first day of trading. On Thursday, vaccine company CanSino Biologics...
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

...CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics...
...– Phosphoinositide 3-kinase deltaCSNK1E (CKI-epsilon) – Casein kinase 1 epsilon BC Staff Ad5-nCoV vosoritide (BMN 111, bmn-111) umbralisib (TGR-1202, rp5264) CanSino Biologics...
BioCentury | Aug 13, 2020
Finance

After biggest STAR listing yet for a biotech, vaccine developer CanSino posts big gain

...gained RMB183.40 (87%) to RMB393.11.Following an offering that raised RMB5.2 billion, or about $750 million, CanSino Biologics...
...Tigermed Consulting Co. Ltd. (SZSE:300347; HKEX:3347), Sanyou Medical (Shanghai:688085), Schrödinger Inc. (NASDAQ:SDGR) and Sinocelltech Ltd. (Shanghai:688520). Paul Bonanos CanSino Biologics...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

...Specially-needed Drug Approval from China on June 25 for another adenovirus-based COVID-19 vaccine: Ad5-nCoV from CanSino Biologics...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

...Oxford University; BNT162b1, another candidate in Pfizer’s and BioNTech’s COVID-19 vaccine program; and Ad5-nCoV from CanSino Biologics...
BioCentury | Jul 27, 2020
Deals

With deal to promote CanSino’s vaccine, Pfizer validates Chinese company’s R&D, manufacturing

...CanSino and China’s newer vaccine companies. Pfizer Inc. (NYSE:PFE) will exclusively promote the vaccine from CanSino Biologics...
...June, received military approval for the product (see “Readouts Raise Expectations” ). Elizabeth S. Eaton, Staff Writer CanSino Biologics...
Items per page:
1 - 10 of 180